Drug intelligence / Profile preview

epinephrine + phentolamine

Development stage: Unknown
Modality: Small Molecules
Administration: Local Injection, Intramuscular, Subcutaneous, Intravenous

Overview

This is not a formulated combination drug product but rather represents a pharmacological interaction. Epinephrine is a catecholamine that stimulates alpha and beta adrenergic receptors, causing vasoconstriction, increased heart rate, and other sympathomimetic effects. Phentolamine is a non-selective alpha-adrenergic antagonist that blocks the effects of epinephrine, particularly at alpha receptors. Phentolamine is clinically used to reverse the vasoconstriction caused by epinephrine, especially in cases of accidental injection of epinephrine into digits or other areas with terminal arteries.

Targets

ADRA1A (α1A)

Beyond the preview

Go deeper on epinephrine + phentolamine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on epinephrine + phentolamine.

Explore the full profile